Novavax, Inc.
A maker of protein-based vaccines against infectious diseases, this Maryland biotech is best known for Nuvaxovid, its COVID-19 shot that delivers pre-made spike proteins grown in moth cells rather than genetic instructions. Founded in 1987 and spun off from its parent IGI in 1995, it gained its Matrix-M immune-boosting adjuvant by buying Sweden's Isconova in 2013. The name blends "nova" (new) with "vax" (vaccine).
Granted 483.1K
Granted 135.5K
Granted 180.5K
Granted 125.3K
Granted 112.6K
Granted 36.0K
Granted 36.0K
Granted 75.3K · Sold 61.2K
Granted 6.7K · Sold 25.0K
Granted 43.9K
Granted 47.4K
Granted 40.7K
Granted 36.0K · Sold 4.2K
Granted 2.1K
Granted 14.3K
Granted 9.5K
Granted 7.9K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Jacobs John CPresident and CEO, Director · 10 transactions | — | 225.7K | 483.1K | — | — |
| O'Hara ElaineEVP, Chief Strategy Officer · 8 transactions | — | 157.1K | 135.5K | — | — |
| Kelly James PatrickEVP, CFO and Treasurer · 16 transactions | +2749% | 130.6K | 180.5K | — | — |
| Casey Mark JEVP, Chief Legal Officer · 8 transactions | — | 101.4K | 125.3K | — | — |
| Trizzino JohnPresident and COO · 12 transactions | +708.4% | 82.0Kas of Mar 2025 | 112.6K | — | — |
| Mott David MDirector · 3 transactions | +82.1% | 79.8K | 36.0K | — | — |
| Douglas RichardDirector · 3 transactions | +96.6% | 73.2K | 36.0K | — | — |
| Dubovsky FilipPresident, R&D · 16 transactions | +55.2% | 66.6Kas of Jun 2024 | 75.3K | — | 61.2K |
| Young James FDirector · 6 transactions | -24.5% | 51.8Kas of Dec 2024 | 6.7K | — | 25.0K |
| Alton Gregg HDirector · 7 transactions | +1154.9% | 47.7K | 43.9K | — | — |
| Rodgers Richard JDirector · 6 transactions | — | 47.4K | 47.4K | — | — |
| McGlynn Margaret GDirector · 7 transactions | +1070.2% | 44.5K | 40.7K | — | — |
| King Rachel K.Director · 4 transactions | +338.5% | 44.1K | 36.0K | — | 4.2K |
| Herrmann John A IIIEVP, Chief Legal Officer · 2 transactions | +11.8% | 17.3Kas of Dec 2023 | 2.1K | — | — |
| Draghia-Akli RuxandraSection 16 · 2 transactions | — | 14.3K | 14.3K | — | — |
| Newton Charles W.Director · 1 transaction | — | 9.5K | 9.5K | — | — |
| Shiver John W.Director · 1 transaction | — | 7.9K | 7.9K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -90.4K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.